Putting Children First: New Models for Pediatric Oncology Drug Development

Sam Blackman, MD, PhD, co-founder and Chief Medical Officer of Day One Biopharmaceuticals, discusses how pediatric oncology drug development can change for the better. Dr. Blackman, who has led the early clinical development of more than 10 novel cancer therapeutics, describes the challenges that have limited the pace of development of new therapeutics for pediatric cancer, new business models that may be capable of changing this dynamic, and how the pediatric oncology ecosystem can work together to enable success.

Presented on January 25, 2022.

Conversations for the Common Good is a guest speaker series hosted by D4CG. We’ve invited thought leaders from across the fields of oncology, clinical trials, and international data sharing to talk about big ideas that can redefine how we think about improving human health. The more we learn from each other, the better we can all work toward the common good.

The views and opinions expressed in Conversations for the Common Good talks are those of the speakers and do not necessarily reflect the official policy or position of Data for the Common Good or the University of Chicago.